Organogenesis Holdings Inc.

NasdaqCM:ORGO Stock Report

Market Cap: US$418.9m

Organogenesis Holdings Dividends and Buybacks

Dividend criteria checks 0/6

Organogenesis Holdings does not have a record of paying a dividend.

Key information

n/a

Dividend yield

0.2%

Buyback Yield

Total Shareholder Yield0.2%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

Recent updates

Organogenesis: Lurking Disruption With Recovery To Follow

Oct 15

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ORGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORGO's dividend payments have been increasing.


Dividend Yield vs Market

Organogenesis Holdings Dividend Yield vs Market
How does ORGO dividend yield compare to the market?
SegmentDividend Yield
Company (ORGO)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.5%
Analyst forecast (ORGO) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ORGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ORGO's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ORGO has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 07:33
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Organogenesis Holdings Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
Ross OsbornCantor Fitzgerald & Co.
Matthew MiksicCredit Suisse